Delivery Order SPE2DB20D9135-SPE2DB24FZY09

Award Date 9/9/24
Potential Completion Date 9/10/24
Potential Value $34K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 order is for the delivery of XTANDI 40 MG CAPSULE 120S, with a completion date of May 20, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This single-award...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $77,604.30, is for the delivery of XTANDI 40 MG CAPSULE 120S to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued up to $499,999,999, which...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $8,622.72, is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 firm fixed-price contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a branded pharmaceutical product. The order has a completion date of June 14, 2024. DMS Pharmaceutical Group holds a larger, single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
This is a Firm Fixed Price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,934.05 order is for the delivery of the prescription drug XTANDI 40 MG CAPSULE 120S, with a completion date of June 25, 2024. The order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,868.10 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a prescription medication, and is not associated with any set-aside program. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, that allows...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,622.72 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product. The delivery order is not associated with any set-aside designation. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a prescription medication, with a performance period ending on June 4, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business based in Park Ridge, Illinois. The $34,490.80 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a pharmaceutical product. The contract has a completion date of February 29, 2024. DMS Pharmaceutical Group holds an indefinite delivery contract (IDC) with the DLA, contract 4600082013 under the SPE2DB program, valued at up to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order, valued at $8,622.72, is for the supply of XTANDI 40 MG CAPSULE 120S for the federal government. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders...
  • SPE2DB20D9135
    Indefinite Delivery Contract
  • SPE2DB20D9135-SPE2DB24FZY09
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $33,923.76, is for the delivery of XTANDI 40 MG CAPSULE 120S over the period of September 10, 2024 to September 10, 2024.

DMS Pharmaceutical Group Inc. holds a larger single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical items to support the recurring medical supply needs of military health facilities worldwide. Through this vehicle, DMS Pharmaceutical Group provides both routine and critical medications to serve the diverse medical requirements of the Department of Defense.

Generated 1/9/25, 9:24 AM